RIGL (Rigel Pharma) Net Profit

RIGL (Rigel Pharmaceuticals, Inc.) - company brandmark

Rigel Pharmaceuticals (RIGL) ensures patient safety through a costly cold chain for drug transportation. A patent shield and stringent FDA oversight create a significant barrier to entry for new players. Effective management relies on R&D expertise and sales transparency, where the current metric stands at 0.32. This chart of the company's market valuation on the GURU.Markets platform visualizes the dynamics of this specialized pharmaceutical business.

RIGL (Rigel Pharmaceuticals) Net Profit history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Rigel Pharmaceuticals, Inc. (RIGL)

- price and consensus price forecast:
Stock Quotes Rigel Corp|RIGL - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Rigel Corp|RIGL - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Rigel Pharmaceuticals|RIGL - Book Capitalization|Market Capitalization to Book Value rigel.com|RIGL - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Rigel Pharmaceuticals|RIGL - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Rigel Pharma|RIGL - Company Total Debt|Debts to Book Capitalization Rigel Corp|RIGL - Company Long-Term Debt|Company Short-Term Indebtedness Rigel Pharmaceuticals|Immediate Liquidity rigel.com
- net income and valuation multiples indicators:
RIGL - Company Net Income
Summary company analysis:Rigel Pharmaceuticals
Core merchandise of Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals (RIGL) monetizes innovative therapies for rare cytopenias, establishing a foundation for future developments. This indicator reflects the daily accumulation of net profit, shaping the objective business value through operating cash flows. Investors should evaluate the vector of this movement to determine the actual efficiency of drug commercialization. Analyzing the company's net profitability allows for a comparison of actual income against financial statements, thereby eliminating the risk of overpaying for the asset.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN - Company Net Income|Final Profit PHAR (Pharming Corp)|NKTR: Net Profit|UPB - Net Financial Result|ZBIO (Zenas Biopharma) - Net Profit|IMNM - Annual Net Income|Net Profit GOSS|KALV - Company Net Income|Company Net Income Septerna Inc SEPN|pieris.com - Company Net Income|SVRA: Net Income|Final Profit ANAB (AnaptysBio Inc)|Astria Pharma (ATXS) - Company Net Income|Profit After Tax ENGN (enGene Corp)|RAPT (RAPT Therapeutics, Inc.) - Net Profit|JBIO: Final Profit|Net Profit ACRS|Net Profit Kyverna Therapeutics Inc. (KYTX)|Company Net Income Tiziana Life Sciences PLC TLSA|Final Profit CABA|VTYX - Company Net Income|theratech.com (THTX) - Net Income|AVTX: Net Profit|Eledon Pharmaceuticals Inc. (ELDN) - Net Profit|AGEN (Agenus Inc) - Net Profit|Net Income Climb Bio, Inc (CLYM)|Net Profit ZURA|ATYR - Company Net Income|Adagene Inc. - Net Income|Net Profit ImageneBio IMA|STTK: Net Income|Equillium, Inc. - Profit After Payment of Taxes|CNTB: Net Profit|IMUX - Net Financial Result|ATRA (Atara Biotherapeutics, Inc.) - Net Profit|Net Income InflaRx GmbH (IFRX)|Net Profit XFOR|Net Profit adicetbio.com (ACET)|Company Net Income Celularity CELU|inmunebio.com - Company Net Income|BRNS - Company Net Income|Net Financial Result Kezar Life Sciences Inc. KZR|SAB Biotherapeutics, Inc (SABS) - Company Net Income|Akari Therapeutics, Plc - Final Profit|ENLV (Enlivex Therapeutics Ltd) - Net Profit|Q32 Bio Corp (QTTB) - Net Financial Result|Net Profit GOVX|Edesa Biotech Inc (EDSA) - Annual Net Income|Company Net Income iBio Corp IBIO|Carisma Therapeutics Inc - Company Net Income|XTLB - Company Net Income|Profit After Tax BOLT|HCWB: Net Profit|Aptevo Therapeutics Inc. - Final Profit|AIM (AIM ImmunoTech) - Net Profit|Net Profit Aditxt Corp|Company Net Income GRI Bio, Inc. (GRI)|XRTX (xortx.com) - Final Profit|Company Net Income Vyome Holdings HIND|REVB - Net Income|Indaptus - Net Profit|SCNI - Net Profit|CALI (calcimedica.com) - Net Income|Affimed N.V. - Final Profit|ALLK (Allakos Inc) - Net Profit|HOOKIPA (HOOK) - Net Financial Result|Company Net Income IGM Biosciences, Inc. (IGMS)|Net Income iTeos Pharma ITOS|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP - Net Income|THRD: Net Income